Pfizer has provided in-line guidance on its 2025 sales and earnings, satisfying investors who were concerned about the company’s management. The pharmaceutical giant forecasts revenue of $61 billion to $64 billion and a profit per share of $2.80 to $3, aligning with analysts’ projections. This move counters claims made by an activist investor that Pfizer is being mismanaged. The news has provided relief to investors, who had been anxious about the company’s future prospects.
Source: https://www.bloomberg.com/news/articles/2024-12-17/pfizer-s-in-line-guidance-offers-relief-to-weary-investors